OncoSil Medical (ASX:OSL) Presentation, FNN Investor Event, May 2018, Sydney Company Presentations May 25, 2018 09:00 AM Email Alerts for: ASX:OSL OncoSil Medical Limited (ASX:OSL) Managing Director & CEO, Daniel Kenny, presents an update on the company's EU commercialisation plans, including CE Mark Certification and Global Pancreatic Cancer programs. Cancer is treated by implantation of radioactive micro-particles into a tumour via ultrasound guided endoscopy with negligible surrounding healthy tissues damage Targeting >$2bn market opportunity to improve standard of care US FDA-approved IDE in place, safety run-in underway EU regulatory approval, CE Marking expected near-term Highly experienced management team; strong clinical and commercial pedigree Manufacturing and logistics optimised for supply of commercial quantities At a potential value inflection point with multiple paths to commercialisation